EA201170801A1 - СПИРОАЗЕПАНОКСАЗОЛИДИНОНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛИЕВОГО КАНАЛА Kv1.3 - Google Patents
СПИРОАЗЕПАНОКСАЗОЛИДИНОНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛИЕВОГО КАНАЛА Kv1.3Info
- Publication number
- EA201170801A1 EA201170801A1 EA201170801A EA201170801A EA201170801A1 EA 201170801 A1 EA201170801 A1 EA 201170801A1 EA 201170801 A EA201170801 A EA 201170801A EA 201170801 A EA201170801 A EA 201170801A EA 201170801 A1 EA201170801 A1 EA 201170801A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methods
- producing
- channel blockers
- spyroazepanoxazolidinones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Настоящее изобретение относится к спироазепаноксазолидинонам как блокаторам потенциалзависимого калиевого канала Kv1.3, фармацевтическим композициям, содержащим эти соединения, способам получения этих соединений, способам получения новых промежуточных соединений, применимых для их синтеза, и способам получения композиций. Настоящее изобретение также относится к применению таких соединений и композиций, в частности к их применению для введения пациентам с целью достижения терапевтического эффекта при лечении диабета, псориаза, ожирения, отторжения трансплантата и воспалительных невропатий, включая аутоиммунные заболевания, опосредуемые Т-клетками, такие как ревматоидный артрит и рассеянный склероз. Эти соединения имеют формулу (1)где символы имеют значения, данные в описании.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12191308P | 2008-12-12 | 2008-12-12 | |
| EP08171421 | 2008-12-12 | ||
| PCT/EP2009/066836 WO2010066840A1 (en) | 2008-12-12 | 2009-12-10 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170801A1 true EA201170801A1 (ru) | 2011-12-30 |
Family
ID=40513443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170801A EA201170801A1 (ru) | 2008-12-12 | 2009-12-10 | СПИРОАЗЕПАНОКСАЗОЛИДИНОНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛИЕВОГО КАНАЛА Kv1.3 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8575148B2 (ru) |
| EP (1) | EP2376501A1 (ru) |
| JP (1) | JP2012511546A (ru) |
| KR (1) | KR20110110165A (ru) |
| CN (1) | CN102333782A (ru) |
| AR (1) | AR074558A1 (ru) |
| AU (1) | AU2009324358A1 (ru) |
| BR (1) | BRPI0922714A2 (ru) |
| CA (1) | CA2743557A1 (ru) |
| CO (1) | CO6390036A2 (ru) |
| CR (1) | CR20110302A (ru) |
| DO (1) | DOP2011000164A (ru) |
| EA (1) | EA201170801A1 (ru) |
| EC (1) | ECSP11011118A (ru) |
| IL (1) | IL212948A0 (ru) |
| MX (1) | MX2011006221A (ru) |
| PE (1) | PE20110772A1 (ru) |
| TW (1) | TW201026708A (ru) |
| WO (1) | WO2010066840A1 (ru) |
| ZA (1) | ZA201104041B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014531469A (ja) * | 2011-10-03 | 2014-11-27 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カ | Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 |
| MA38135B1 (fr) * | 2012-10-29 | 2018-11-30 | Hoffmann La Roche | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium |
| TWI698438B (zh) | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| TWI701249B (zh) | 2015-03-13 | 2020-08-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| CN109053751A (zh) * | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
| US20220356176A1 (en) * | 2019-06-12 | 2022-11-10 | The Johns Hopkins University | Kv11.1-3.1 INHIBITING METHODS AND COMPOSITIONS |
| CN111574537B (zh) * | 2020-05-20 | 2022-11-15 | 成都药明康德新药开发有限公司 | 叔丁基-8-氧杂-3,11-二氮杂螺[5.6]十二烷-3-甲酸基酯的合成方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
-
2009
- 2009-12-09 TW TW098142079A patent/TW201026708A/zh unknown
- 2009-12-09 AR ARP090104760A patent/AR074558A1/es unknown
- 2009-12-10 BR BRPI0922714A patent/BRPI0922714A2/pt not_active IP Right Cessation
- 2009-12-10 US US13/133,042 patent/US8575148B2/en not_active Expired - Fee Related
- 2009-12-10 CN CN2009801494792A patent/CN102333782A/zh active Pending
- 2009-12-10 AU AU2009324358A patent/AU2009324358A1/en not_active Abandoned
- 2009-12-10 MX MX2011006221A patent/MX2011006221A/es not_active Application Discontinuation
- 2009-12-10 PE PE2011001198A patent/PE20110772A1/es not_active Application Discontinuation
- 2009-12-10 JP JP2011540106A patent/JP2012511546A/ja active Pending
- 2009-12-10 CA CA2743557A patent/CA2743557A1/en not_active Abandoned
- 2009-12-10 EA EA201170801A patent/EA201170801A1/ru unknown
- 2009-12-10 EP EP09765127A patent/EP2376501A1/en not_active Withdrawn
- 2009-12-10 KR KR1020117016047A patent/KR20110110165A/ko not_active Application Discontinuation
- 2009-12-10 WO PCT/EP2009/066836 patent/WO2010066840A1/en active Application Filing
-
2011
- 2011-05-17 IL IL212948A patent/IL212948A0/en unknown
- 2011-05-31 DO DO2011000164A patent/DOP2011000164A/es unknown
- 2011-05-31 ZA ZA2011/04041A patent/ZA201104041B/en unknown
- 2011-06-03 CR CR20110302A patent/CR20110302A/es not_active Application Discontinuation
- 2011-06-08 CO CO11070889A patent/CO6390036A2/es not_active Application Discontinuation
- 2011-06-09 EC EC2011011118A patent/ECSP11011118A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6390036A2 (es) | 2012-02-29 |
| TW201026708A (en) | 2010-07-16 |
| ECSP11011118A (es) | 2011-07-29 |
| PE20110772A1 (es) | 2011-10-19 |
| ZA201104041B (en) | 2012-11-28 |
| US20110237569A1 (en) | 2011-09-29 |
| EP2376501A1 (en) | 2011-10-19 |
| WO2010066840A1 (en) | 2010-06-17 |
| BRPI0922714A2 (pt) | 2016-01-05 |
| AU2009324358A1 (en) | 2011-06-23 |
| US8575148B2 (en) | 2013-11-05 |
| MX2011006221A (es) | 2011-06-28 |
| IL212948A0 (en) | 2011-07-31 |
| KR20110110165A (ko) | 2011-10-06 |
| CR20110302A (es) | 2011-10-27 |
| CN102333782A (zh) | 2012-01-25 |
| DOP2011000164A (es) | 2011-06-30 |
| AR074558A1 (es) | 2011-01-26 |
| CA2743557A1 (en) | 2010-06-17 |
| JP2012511546A (ja) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170801A1 (ru) | СПИРОАЗЕПАНОКСАЗОЛИДИНОНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛИЕВОГО КАНАЛА Kv1.3 | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| EA201690899A1 (ru) | Оксазепины в качестве модуляторов ионных каналов | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| WO2011056985A3 (en) | Substituted heterocyclic compounds | |
| IN2012DN05467A (ru) | ||
| EA201390381A1 (ru) | Триазиноксадиазолы | |
| EA201790417A3 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| IN2014KN01075A (ru) | ||
| EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
| EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
| EA201200794A1 (ru) | Триазолопиридины | |
| CY1112725T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| EA201270575A1 (ru) | Соединения | |
| EA201291272A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
| CY1117705T1 (el) | Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων | |
| EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
| EA201301181A1 (ru) | Триазолопиридины | |
| MD4583B1 (ru) | Новые бициклические пиридиноны | |
| EA201390010A1 (ru) | Замещенные триазолопиридины | |
| EA201001522A1 (ru) | Новые p2x7r антагонисты и их применение | |
| FR2981934B1 (fr) | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена |